ORIBASE PHARMA is a French Contract Research Organization dedicated to the design and synthesis of kinase inhibitors. ORIBASE PHARMA developed a unique technology platform for efficient drug discovery consisting in chemoinformatics and organic chemistry processes. ORIBASE PHARMA has currently a portfolio of five kinase inhibitors in pre-clinical development. During its research programs, ORIBASE PHARMA developed ways to obtain efficiently hard-to-synthesize aza-heterocycles.

CHEM-X-INFINITY is pleased to announce it has signed a partnership with ORIBASE PHARMA for the design of original libraries focused on kinase inhibition. The libraries will explore the diversity space around ORIBASE PHARMA’s original scaffolds. The molecules are poorly described in the literature and are free of patentability. They are designed to fully respect the Lipinski rules to offer ideal compounds for first intention screenings.

The partnership is a long term commitment with the objective to develop several thematic libraries focused on kinases. The first library having applications in the oncology field will be released in December, 2011.